6oik: Difference between revisions

From Proteopedia
Jump to navigationJump to search
← Older edit
OCA (talk | contribs)
Bots, Bureaucrats, journal, Administrators
3,331,615 edits
No edit summary
OCA (talk | contribs)
Bots, Bureaucrats, journal, Administrators
3,331,615 edits
No edit summary
 
Line 3: Line 3:
<SX load='6oik' size='340' side='right' viewer='molstar' caption='[[6oik]], [[Resolution|resolution]] 3.60&Aring;' scene=''>
<SX load='6oik' size='340' side='right' viewer='molstar' caption='[[6oik]], [[Resolution|resolution]] 3.60&Aring;' scene=''>
== Structural highlights ==
== Structural highlights ==
<table><tr><td colspan='2'>[[6oik]] is a 5 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human] and [http://en.wikipedia.org/wiki/Lk3_transgenic_mice Lk3 transgenic mice]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6OIK OCA]. For a <b>guided tour on the structure components</b> use [http://proteopedia.org/fgij/fg.htm?mol=6OIK FirstGlance]. <br>
<table><tr><td colspan='2'>[[6oik]] is a 5 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] and [https://en.wikipedia.org/wiki/Mus_musculus Mus musculus]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6OIK OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6OIK FirstGlance]. <br>
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=2CU:3-AMINO-5-CHLORO-N-CYCLOPROPYL-4-METHYL-6-[2-(4-METHYLPIPERAZIN-1-YL)-2-OXOETHOXY]THIENO[2,3-B]PYRIDINE-2-CARBOXAMIDE'>2CU</scene>, <scene name='pdbligand=IXO:4-(4,5-DIHYDRO-1,2-OXAZOL-3-YLOXY)-N,N,N-TRIMETHYLBUT-2-YN-1-AMINIUM'>IXO</scene></td></tr>
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">Electron Microscopy, [[Resolution|Resolution]] 3.6&#8491;</td></tr>
<tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">CHRM2 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN]), GNAO1 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN]), GNB1 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN]), GNG2 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=2CU:3-AMINO-5-CHLORO-N-CYCLOPROPYL-4-METHYL-6-[2-(4-METHYLPIPERAZIN-1-YL)-2-OXOETHOXY]THIENO[2,3-B]PYRIDINE-2-CARBOXAMIDE'>2CU</scene>, <scene name='pdbligand=IXO:4-(4,5-DIHYDRO-1,2-OXAZOL-3-YLOXY)-N,N,N-TRIMETHYLBUT-2-YN-1-AMINIUM'>IXO</scene></td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://proteopedia.org/fgij/fg.htm?mol=6oik FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6oik OCA], [http://pdbe.org/6oik PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6oik RCSB], [http://www.ebi.ac.uk/pdbsum/6oik PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6oik ProSAT]</span></td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6oik FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6oik OCA], [https://pdbe.org/6oik PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6oik RCSB], [https://www.ebi.ac.uk/pdbsum/6oik PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6oik ProSAT]</span></td></tr>
</table>
</table>
== Disease ==
== Disease ==
[[http://www.uniprot.org/uniprot/ACM2_HUMAN ACM2_HUMAN]] Disease susceptibility is associated with variations affecting the gene represented in this entry. [[http://www.uniprot.org/uniprot/GNAO_HUMAN GNAO_HUMAN]] Early infantile epileptic encephalopathy. The disease is caused by mutations affecting the gene represented in this entry.  The disease is caused by mutations affecting the gene represented in this entry.  
[https://www.uniprot.org/uniprot/ACM2_HUMAN ACM2_HUMAN] Disease susceptibility is associated with variations affecting the gene represented in this entry.
== Function ==
== Function ==
[[http://www.uniprot.org/uniprot/GBG2_HUMAN GBG2_HUMAN]] Guanine nucleotide-binding proteins (G proteins) are involved as a modulator or transducer in various transmembrane signaling systems. The beta and gamma chains are required for the GTPase activity, for replacement of GDP by GTP, and for G protein-effector interaction (By similarity). [[http://www.uniprot.org/uniprot/ACM2_HUMAN ACM2_HUMAN]] The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. [[http://www.uniprot.org/uniprot/GBB1_HUMAN GBB1_HUMAN]] Guanine nucleotide-binding proteins (G proteins) are involved as a modulator or transducer in various transmembrane signaling systems. The beta and gamma chains are required for the GTPase activity, for replacement of GDP by GTP, and for G protein-effector interaction.<ref>PMID:18611381</ref>  [[http://www.uniprot.org/uniprot/GNAO_HUMAN GNAO_HUMAN]] Guanine nucleotide-binding proteins (G proteins) are involved as modulators or transducers in various transmembrane signaling systems. The G(o) protein function is not clear. Stimulated by RGS14.  
[https://www.uniprot.org/uniprot/ACM2_HUMAN ACM2_HUMAN] The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition.
<div style="background-color:#fffaf0;">
<div style="background-color:#fffaf0;">
== Publication Abstract from PubMed ==
== Publication Abstract from PubMed ==
Line 23: Line 23:


==See Also==
==See Also==
*[[Antibody 3D structures|Antibody 3D structures]]
*[[GTP-binding protein 3D structures|GTP-binding protein 3D structures]]
*[[Muscarinic acetylcholine receptor|Muscarinic acetylcholine receptor]]
*[[Muscarinic acetylcholine receptor|Muscarinic acetylcholine receptor]]
*[[Transducin 3D structures|Transducin 3D structures]]
*[[Transducin 3D structures|Transducin 3D structures]]
*[[3D structures of non-human antibody|3D structures of non-human antibody]]
== References ==
== References ==
<references/>
<references/>
__TOC__
__TOC__
</SX>
</SX>
[[Category: Human]]
[[Category: Homo sapiens]]
[[Category: Large Structures]]
[[Category: Large Structures]]
[[Category: Lk3 transgenic mice]]
[[Category: Mus musculus]]
[[Category: Kobilka, B]]
[[Category: Kobilka B]]
[[Category: Maeda, S]]
[[Category: Maeda S]]
[[Category: Qianhui, Q]]
[[Category: Qianhui Q]]
[[Category: Skiniotis, G]]
[[Category: Skiniotis G]]
[[Category: G-protein coupled receptor-g-protein complex]]
[[Category: Neurotransmitter receptor]]
[[Category: Signaling protein]]

Latest revision as of 05:32, 21 November 2024

Muscarinic acetylcholine receptor 2-Go complex

Loading...

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "https://proteopedia.org/index.php?title=6oik&oldid=4275689"